Find any stock by ticker or company name
NGM – Real Time Price. Currency in USD
7.49
-0.55 (-6.84%)
Market open: Aug 12, 2026, 1:40 PM EDT
7.80
-0.24 (-3.05%)
Previous after-hours: Aug 11, 2026, 7:34 PM EDT
Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision therapies to treat solid tumors. The company’s proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer. It focuses on assessing the safety and efficacy of bel-sar in treating a range of other solid tumors, including bladder cancer. The company was incorporated in 2009 and is headquartered in Boston, Massachusetts.
| Name | Position |
|---|---|
| Dr. Anthony Daniels M.D. | VP & Therapeutic Area of Head Ocular Oncology |
| Dr. J. Jill Hopkins M.D. | Chief Medical Officer & President of Research and Development |
| Mr. Joe McQuaid M.D. | VP & Therapeutic Area Head of Urologic Oncology |
| Mr. Patrick Nealon | Senior Vice President of Clinical Development Operations |
| Ms. Amy Elazzouzi | Interim Principal Accounting Officer, Senior VP of Finance & Treasurer |
| Ms. Natalie C. Holles | President, CEO & Director |
| Date | Type | Document |
|---|---|---|
| 2026-08-11 | S-3 | d140546ds3.htm |
| 2026-08-05 | 8-K | aura-20260805.htm |
| 2026-07-08 | 8-K | aura-20260703.htm |
| 2026-06-29 | DEF 14A | aura-20260624.htm |
| 2026-06-17 | PRE 14A | aura-20260617.htm |
| 2026-06-11 | 8-K | aura-20260611.htm |
| 2026-05-19 | S-8 | d118275ds8.htm |
| 2026-05-11 | 8-K | aura-20260511.htm |
| 2026-05-11 | 10-Q | aura-20260331.htm |
| 2026-05-05 | 8-K | d133115d8k.htm |